Nucleic Acid Research Institute
Kodak leaving R&D joint venture with ICN. Under the exit agreement ICN retains all drugs in research, scientific personnel, lab equipment and facilities. NARI was formed in 1985. Kodak, which recently acquired drug R&D capability with the acquisition of Sterling, previously owned 5% of ICN and 10% of ICN subsidiary Viratek. Those positions were sold in March 1987.
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”